5.35 USD
-0.03 (-0.56%)
5.3125 USD
-0.04 (-0.7%)
Overall MNKD gets a fundamental rating of 5 out of 10. We evaluated MNKD against 533 industry peers in the Biotechnology industry. MNKD has only an average score on both its financial health and profitability. MNKD is not priced too expensively while it is growing strongly. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
MNKD had positive earnings in the past year.
MNKD had a positive operating cash flow in the past year.
MNKD had negative earnings in 4 of the past 5 years.
In multiple years MNKD reported negative operating cash flow during the last 5 years.
1.2 Ratios
With an excellent Return On Assets value of 5.81%, MNKD belongs to the best of the industry, outperforming 92.32% of the companies in the same industry.
MNKD has a better Return On Invested Capital (18.48%) than 97.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.81% | ||
| ROE | N/A | ||
| ROIC | 18.48% |
ROA(3y)-8.37%
ROA(5y)-20.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of MNKD (9.16%) is better than 91.57% of its industry peers.
Looking at the Operating Margin, with a value of 27.48%, MNKD belongs to the top of the industry, outperforming 96.25% of the companies in the same industry.
Looking at the Gross Margin, with a value of 78.49%, MNKD belongs to the top of the industry, outperforming 84.27% of the companies in the same industry.
MNKD's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.48% | ||
| PM (TTM) | 9.16% | ||
| GM | 78.49% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.44%
GM growth 5Y5.99%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), MNKD is creating value.
MNKD has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, MNKD has more shares outstanding
Compared to 1 year ago, MNKD has an improved debt to assets ratio.
2.2 Solvency
MNKD has an Altman-Z score of -5.36. This is a bad value and indicates that MNKD is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of MNKD (-5.36) is worse than 62.17% of its industry peers.
MNKD has a debt to FCF ratio of 8.39. This is a slightly negative value and a sign of low solvency as MNKD would need 8.39 years to pay back of all of its debts.
MNKD's Debt to FCF ratio of 8.39 is amongst the best of the industry. MNKD outperforms 90.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 8.39 | ||
| Altman-Z | -5.36 |
ROIC/WACC2.2
WACC8.39%
2.3 Liquidity
A Current Ratio of 3.29 indicates that MNKD has no problem at all paying its short term obligations.
The Current ratio of MNKD (3.29) is worse than 60.30% of its industry peers.
A Quick Ratio of 3.04 indicates that MNKD has no problem at all paying its short term obligations.
MNKD's Quick ratio of 3.04 is on the low side compared to the rest of the industry. MNKD is outperformed by 60.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.29 | ||
| Quick Ratio | 3.04 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 174.00% over the past year.
The Revenue has grown by 17.44% in the past year. This is quite good.
Measured over the past years, MNKD shows a very strong growth in Revenue. The Revenue has been growing by 35.29% on average per year.
EPS 1Y (TTM)174%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%235%
Revenue 1Y (TTM)17.44%
Revenue growth 3Y55.86%
Revenue growth 5Y35.29%
Sales Q2Q%17.2%
3.2 Future
MNKD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 52.41% yearly.
MNKD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 18.25% yearly.
EPS Next Y18.4%
EPS Next 2Y5.62%
EPS Next 3Y32.25%
EPS Next 5Y52.41%
Revenue Next Year14.19%
Revenue Next 2Y16.74%
Revenue Next 3Y15.12%
Revenue Next 5Y18.25%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
MNKD is valuated quite expensively with a Price/Earnings ratio of 38.21.
Compared to the rest of the industry, the Price/Earnings ratio of MNKD indicates a rather cheap valuation: MNKD is cheaper than 91.01% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.31, MNKD is valued a bit more expensive.
MNKD is valuated quite expensively with a Price/Forward Earnings ratio of 59.94.
Compared to the rest of the industry, the Price/Forward Earnings ratio of MNKD indicates a rather cheap valuation: MNKD is cheaper than 88.95% of the companies listed in the same industry.
MNKD's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 36.59.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 38.21 | ||
| Fwd PE | 59.94 |
4.2 Price Multiples
94.38% of the companies in the same industry are more expensive than MNKD, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of MNKD indicates a rather cheap valuation: MNKD is cheaper than 92.70% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 37.86 | ||
| EV/EBITDA | 16.67 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates MNKD does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as MNKD's earnings are expected to grow with 32.25% in the coming years.
PEG (NY)2.08
PEG (5Y)N/A
EPS Next 2Y5.62%
EPS Next 3Y32.25%
5. Dividend
5.1 Amount
MNKD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
5.35
-0.03 (-0.56%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners55.89%
Inst Owner Change2.14%
Ins Owners1.51%
Ins Owner Change-0.94%
Market Cap1.64B
Revenue(TTM)313.79M
Net Income(TTM)28.75M
Analysts85.71
Price Target9.24 (72.71%)
Short Float %7.63%
Short Ratio5.26
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)53.26%
Min EPS beat(2)-100%
Max EPS beat(2)206.52%
EPS beat(4)1
Avg EPS beat(4)19.34%
Min EPS beat(4)-100%
Max EPS beat(4)206.52%
EPS beat(8)2
Avg EPS beat(8)-31.68%
EPS beat(12)5
Avg EPS beat(12)-2.87%
EPS beat(16)6
Avg EPS beat(16)-4.99%
Revenue beat(2)1
Avg Revenue beat(2)-2.11%
Min Revenue beat(2)-4.55%
Max Revenue beat(2)0.33%
Revenue beat(4)3
Avg Revenue beat(4)-0.74%
Min Revenue beat(4)-4.55%
Max Revenue beat(4)0.9%
Revenue beat(8)6
Avg Revenue beat(8)1.65%
Revenue beat(12)8
Avg Revenue beat(12)2.45%
Revenue beat(16)11
Avg Revenue beat(16)3.58%
PT rev (1m)-14.27%
PT rev (3m)-2.03%
EPS NQ rev (1m)-44.42%
EPS NQ rev (3m)-64.28%
EPS NY rev (1m)0%
EPS NY rev (3m)-30.11%
Revenue NQ rev (1m)13.09%
Revenue NQ rev (3m)15.87%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.23%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 38.21 | ||
| Fwd PE | 59.94 | ||
| P/S | 5.24 | ||
| P/FCF | 37.86 | ||
| P/OCF | 33.63 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 16.67 |
EPS(TTM)0.14
EY2.62%
EPS(NY)0.09
Fwd EY1.67%
FCF(TTM)0.14
FCFY2.64%
OCF(TTM)0.16
OCFY2.97%
SpS1.02
BVpS-0.15
TBVpS-0.17
PEG (NY)2.08
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.81% | ||
| ROE | N/A | ||
| ROCE | 22.37% | ||
| ROIC | 18.48% | ||
| ROICexc | 48.2% | ||
| ROICexgc | 50.4% | ||
| OM | 27.48% | ||
| PM (TTM) | 9.16% | ||
| GM | 78.49% | ||
| FCFM | 13.83% |
ROA(3y)-8.37%
ROA(5y)-20.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.44%
GM growth 5Y5.99%
F-Score8
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 8.39 | ||
| Debt/EBITDA | 3.59 | ||
| Cap/Depr | 64.99% | ||
| Cap/Sales | 1.74% | ||
| Interest Coverage | 9.12 | ||
| Cash Conversion | 51.63% | ||
| Profit Quality | 150.89% | ||
| Current Ratio | 3.29 | ||
| Quick Ratio | 3.04 | ||
| Altman-Z | -5.36 |
F-Score8
WACC8.39%
ROIC/WACC2.2
Cap/Depr(3y)397.13%
Cap/Depr(5y)337.1%
Cap/Sales(3y)10.78%
Cap/Sales(5y)10.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)174%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%235%
EPS Next Y18.4%
EPS Next 2Y5.62%
EPS Next 3Y32.25%
EPS Next 5Y52.41%
Revenue 1Y (TTM)17.44%
Revenue growth 3Y55.86%
Revenue growth 5Y35.29%
Sales Q2Q%17.2%
Revenue Next Year14.19%
Revenue Next 2Y16.74%
Revenue Next 3Y15.12%
Revenue Next 5Y18.25%
EBIT growth 1Y48.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y237.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y386.62%
OCF growth 3YN/A
OCF growth 5YN/A
MANNKIND CORP / MNKD FAQ
What is the fundamental rating for MNKD stock?
ChartMill assigns a fundamental rating of 5 / 10 to MNKD.
What is the valuation status for MNKD stock?
ChartMill assigns a valuation rating of 5 / 10 to MANNKIND CORP (MNKD). This can be considered as Fairly Valued.
Can you provide the profitability details for MANNKIND CORP?
MANNKIND CORP (MNKD) has a profitability rating of 5 / 10.
Can you provide the expected EPS growth for MNKD stock?
The Earnings per Share (EPS) of MANNKIND CORP (MNKD) is expected to grow by 18.4% in the next year.